<div id="readability-page-1"><p>Price T Rowe Associates Inc. MD acquired a new stake in  Grail, Inc. (NASDAQ:GRAL - Free Report) during the 4th quarter, according to its most recent disclosure with the Securities &amp; Exchange Commission. The firm acquired 24,520 shares of the company's stock, valued at approximately $438,000. Price T Rowe Associates Inc. MD owned approximately 0.07% of Grail as of its most recent SEC filing.</p><ul><li>GRAIL: Biotech Stock Targeting $100B Cancer Market</li></ul><p>A number of other hedge funds have also recently made changes to their positions in the company. C2P Capital Advisory Group LLC d.b.a. Prosperity Capital Advisors bought a new position in shares of  Grail during the fourth quarter worth about $244,000.  Moloney Securities Asset Management LLC acquired a new stake in  Grail in the fourth quarter valued at approximately $559,000.  Rhumbline Advisers acquired a new stake in  Grail in the fourth quarter valued at approximately $456,000.  Wesbanco Bank Inc. bought a new stake in  Grail during the fourth quarter worth $523,000.  Finally, Slow Capital Inc. bought a new stake in  Grail during the fourth quarter worth $2,379,000. </p><h2>Analysts Set New Price Targets</h2><p>Several research firms have weighed in on GRAL. Canaccord Genuity Group assumed coverage on Grail in a research report on Monday, April 21st. They issued a &#34;buy&#34; rating and a $32.00 price objective on the stock. Morgan Stanley upped their target price on Grail from $16.00 to $20.00 and gave the stock an &#34;equal weight&#34; rating in a research note on Tuesday, March 18th.</p><ul><li>Strategic Buy Lights Up This Biotech Stock: Time to Invest?</li></ul><p><b>Check Out Our Latest Analysis on GRAL</b></p><h2>Insiders Place Their Bets</h2><p>In other Grail news, President Joshua J. Ofman sold 48,213 shares of the stock in a transaction dated Friday, May 2nd. The stock was sold at an average price of $33.93, for a total value of $1,635,867.09. Following the transaction, the president now owns 511,460 shares of the company's stock, valued at approximately $17,353,837.80. This represents a 8.61% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities &amp; Exchange Commission, which can be accessed through the SEC website. Also, CFO Aaron Freidin sold 1,816 shares of the stock in a transaction dated Friday, March 7th. The shares were sold at an average price of $31.20, for a total value of $56,659.20. Following the completion of the transaction, the chief financial officer now directly owns 335,170 shares in the company, valued at approximately $10,457,304. This represents a 0.54% decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 194,948 shares of company stock valued at $6,583,130. 1.85% of the stock is currently owned by corporate insiders. </p><h2>Grail Price Performance</h2><p>Shares of NASDAQ GRAL opened at $42.89 on Wednesday. The stock's 50-day moving average is $29.69 and its 200 day moving average is $26.15. Grail, Inc. has a 1-year low of $12.33 and a 1-year high of $63.99. </p><p>Grail (NASDAQ:GRAL - Get Free Report) last announced its quarterly earnings results on Tuesday, May 13th. The company reported ($3.10) EPS for the quarter, topping analysts' consensus estimates of ($4.03) by $0.93. The company had revenue of $31.84 million during the quarter, compared to analysts' expectations of $35.80 million.  Equities research analysts expect that  Grail, Inc. will post -15.15 earnings per share for the current year. </p><h2>Grail Profile</h2> (Free Report)<p>GRAIL, Inc operates as a commercial-stage healthcare company, which engages in the development of a technology for early detection of cancer. It utilizes machine learning, software, and automation to detect and identify multiple deadly cancer types in earlier stages. The company was founded by Jeffrey T.</p><h2>Featured Articles</h2><ul><li>Five stocks we like better than Grail</li><li>Top Stocks Investing in 5G Technology</li><li>NVIDIA Stock Surges on Bullish News: How High Could It Climb?</li><li>Dividend Capture Strategy: What You Need to Know</li><li>Why Boeing May Be Ready to Take Off After Latest Developments</li><li>What is diluted earnings per share (Diluted EPS)?</li><li>eBay Nears Big Breakout: Time to Buy the Under-the-Radar Winner?</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9R1JBTA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9R1JBTA"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Grail Right Now?</h2><p>Before you consider Grail, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Grail wasn't on the list.</p><p>While Grail currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

GRAL

TROW

<p>Price T Rowe Associates Inc. MD acquired 24,520 shares of Grail, Inc. (NASDAQ:GRAL) valued at approximately $438,000 during the 4th quarter. Other hedge funds also increased their stakes in Grail. Analysts have set new price targets, with Canaccord Genuity issuing a "buy" rating and a $32.00 price objective, while Morgan Stanley raised their target from $16.00 to $20.00. Grail reported a quarterly EPS of ($3.10), exceeding estimates, with revenue of $31.84 million. The stock opened at $42.89, with a 1-year range of $12.33 to $63.99.</p>

Price T Rowe Associates Inc. MD Acquires New Shares in Grail, Inc. (NASDAQ:GRAL)